Published in Adv Exp Med Biol on January 01, 2012
Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature (2001) 25.15
Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science (2003) 17.57
Activation of the interferon system by short-interfering RNAs. Nat Cell Biol (2003) 8.63
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
RIP1 is an essential mediator of Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol (2004) 5.74
Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med (2008) 4.46
Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol (2003) 4.15
The Toll receptor family and microbial recognition. Trends Microbiol (2000) 3.01
TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol (2005) 2.94
A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol (2006) 2.89
A FADD-dependent innate immune mechanism in mammalian cells. Nature (2004) 2.50
Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol (2004) 2.42
Toll-like receptor 3 is a potent negative regulator of axonal growth in mammals. J Neurosci (2007) 1.88
Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol (2004) 1.67
Innate immunity in the retina: Toll-like receptor (TLR) signaling in human retinal pigment epithelial cells. J Neuroimmunol (2004) 1.65
Toll-like receptor 3 is a negative regulator of embryonic neural progenitor cell proliferation. J Neurosci (2008) 1.55
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A (2009) 1.36
Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun (2010) 1.33
Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther (2009) 1.19
Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology (2010) 1.18
Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol (2010) 0.98
A tag-single nucleotide polymorphisms approach to the vascular endothelial growth factor-A gene in age-related macular degeneration. Mol Vis (2007) 0.98
Toll-like receptor polymorphisms and age-related macular degeneration: replication in three case-control samples. Invest Ophthalmol Vis Sci (2009) 0.95
Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA. Exp Eye Res (2010) 0.95
Suppression of laser-induced choroidal neovascularization by nontargeted siRNA. Invest Ophthalmol Vis Sci (2010) 0.88
Infectious agents and ARMD: a connection? Am J Ophthalmol (2004) 0.77
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med (2008) 4.46
DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature (2011) 3.90
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 3.17
DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88. Cell (2012) 2.81
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med (2003) 2.52
Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med (2009) 2.39
CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature (2009) 2.39
HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia (2006) 1.53
Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J Clin Invest (2006) 1.36
Small interfering RNA-induced TLR3 activation inhibits blood and lymphatic vessel growth. Proc Natl Acad Sci U S A (2009) 1.36
Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci (2003) 1.34
Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci (2003) 1.22
Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci (2005) 1.13
TLR-independent and P2X7-dependent signaling mediate Alu RNA-induced NLRP3 inflammasome activation in geographic atrophy. Invest Ophthalmol Vis Sci (2013) 1.11
Short-interfering RNAs induce retinal degeneration via TLR3 and IRF3. Mol Ther (2011) 1.09
Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. Elife (2013) 1.06
Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea (2003) 1.05
CCR2 mediates increases in glial activation caused by exposure to HIV-1 Tat and opiates. J Neuroimmunol (2006) 1.04
Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor sVEGFR-2. Clin Cancer Res (2010) 0.99
ERK1/2 activation is a therapeutic target in age-related macular degeneration. Proc Natl Acad Sci U S A (2012) 0.99
Distinct CCR2(+) Gr1(+) cells control growth of the Yersinia pestis ΔyopM mutant in liver and spleen during systemic plague. Infect Immun (2010) 0.97
Unique homologous siRNA blocks hypoxia-induced VEGF upregulation in human corneal cells and inhibits and regresses murine corneal neovascularization. Cornea (2007) 0.93
Soluble VEGFR-2: an antilymphangiogenic variant of VEGF receptors. Ann N Y Acad Sci (2010) 0.93
Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol (2002) 0.91
Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration. ACS Nano (2013) 0.91
Molecular docking and analysis of interactions between vascular endothelial growth factor (VEGF) and SPARC protein. J Mol Graph Model (2007) 0.90
Dual suppression of hemangiogenesis and lymphangiogenesis by splice-shifting morpholinos targeting vascular endothelial growth factor receptor 2 (KDR). FASEB J (2012) 0.89
Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. J Biol Chem (2008) 0.87
Aquaporin-1 expression is decreased in human and mouse corneal endothelial dysfunction. Mol Vis (2004) 0.85
Systemic soluble Tie2 expression inhibits and regresses corneal neovascularization. Biochem Biophys Res Commun (2005) 0.83
The multifactorial nature of retinal vascular disease. Ophthalmologica (2010) 0.82
The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med (2010) 0.82
Retinal angiogenesis suppression through small molecule activation of p53. J Clin Invest (2013) 0.80
Fifty years later: the disk goes to the prom. J Clin Invest (2008) 0.77
Complement Activation and Inhibition in Retinal Diseases. Dev Ophthalmol (2015) 0.77
Mammary cancer gene therapy targeting lymphangiogenesis: VEGF-C siRNA and soluble VEGF receptor-2, a splicing variant. Med Mol Morphol (2012) 0.77
Toward a higher fidelity model of AMD. Adv Exp Med Biol (2008) 0.76
Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer. Invest Ophthalmol Vis Sci (2012) 0.76
Triamcinolone crystal size. Ophthalmology (2010) 0.76
Age-related eye disease study caveats. Arch Ophthalmol (2002) 0.75
Clocking in on diabetic retinopathy. Diabetes (2013) 0.75
Retinoblastoma with cataract and ectopia lentis. J AAPOS (2003) 0.75
Eyelid disease. Ophthalmology (2005) 0.75